Some glioma cell products are linked to DC dysfunction, including R-2-hydroxyglutarate (R-2-HG), fibrinogen-like protein 2 (FGL2), Nrf2, etc. In high grade glioma (HGG) patients with IDHmut, reprogramming mediated by the tumor metabolite R-2-HG leads to poor antigen presentation of DCs (66). This evidence concerns the gene FGL2 and central nervous system cancer.